Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.43 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.39 |
| ▸ | FYN | P06241 | 3/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17752364 | 0.88 | PDGFRB (0.52) | KITPDGFRBPDGFRAFYNALDH1A1 | |
| SCHEMBL12268833 | 0.81 | NFE2L2 (0.44) | ERN1PDGFRBPDGFRACYP3A4TSHR | |
| SCHEMBL16303551 | 0.76 | FPR2 (0.36) | KITABCB1ERN1ABCC1PDGFRB | |
| SCHEMBL16437067 | 0.74 | FFAR1 (0.46) | ERN1PDGFRBPDGFRACYP3A4 | |
| SCHEMBL17752358 | 0.74 | SCN9A (0.37) | KITABCB1ALDH1A1 | |
| SCHEMBL15010355 | 0.73 | ENPP2 (0.44) | KITABCB1ERN1ABCC1PDGFRB | |
| SCHEMBL15011357 | 0.73 | KIT (0.44) | KITABCB1ERN1ABCC1FYN | |
| SCHEMBL16311804 | 0.73 | ABCB1 (0.43) | KITABCB1ERN1ABCC1PDGFRB | |
| SCHEMBL7112672 | 0.72 | ABCB1 (0.40) | KITABCB1ERN1ABCC1 | |
| SCHEMBL8402696 | 0.72 | CA12 (0.65) | ALDH1A1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | AMGEN INC. | 2016-05-19 | — | — | US | disclosed |
| US-9012443-B2 | Bicyclic aryl and heteroaryl sodium channel inhibitors | AMGEN INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | AMGEN INC. (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150339-A1 | Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors | SCN1A, SCN1B, CACNA1B | KIT 4034/4885ABCB1 156/4885ERN1 3075/4885 |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | SCN7A, SCN1A, SCN5A | KIT 3135/4885ABCB1 292/4885ERN1 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.